ONC

BeOne Medicines Ltd.

Pharmaceutical Preparations · SIC 2834CIK 1651308Held by 3 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$5.34B

Net Income FY2025

$0.29B

EPS (Basic, as reported)

$0.20

Net Margin FY2025

5.4%

ROE FY2025

6.6%

Total Equity

$4.36B

Shares Out

1.48B

Business description

BeOne Medicines Ltd. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2014–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 1 → 5,343 +159.5% CAGR

Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue12381984283091,1761,4162,4593,8105,343

Cost of revenue0(5)(29)(71)(71)(165)(286)———

Gross profit—————1,0111,1292,0793,2164,674

Research & development(98)(269)(679)(927)(1,295)(1,459)(1,641)(1,779)(1,953)(2,146)

Selling, general & administrative(20)(63)(195)(388)(600)(990)(1,278)(1,505)(1,831)(2,081)

General & administrative(20)—————————

Total operating expenses(118)(337)(904)(1,388)(1,967)(2,615)(3,206)(3,287)(3,784)(4,227)

Operating income(117)(98)(706)(960)(1,658)(1,439)(1,790)(1,208)(568)447

Interest expense——(13)(15)(18)(29)(22)(4)(22)(58)

Interest & investment income———————787071

Other income (expense), net011273716(224)308(13)(43)

Pre-tax income(119)(91)(690)(944)(1,618)(1,439)(1,961)(826)(533)417

Income tax expense0(2)(16)(7)(18)(25)(43)(56)(112)(130)

Net income(119)(93)(674)(949)(1,597)(1,413)(2,004)(882)(645)287

EPS — basic———($1.22)($1.47)($1.17)($1.49)($0.65)($0.47)$0.20

EPS — diluted———($1.22)($1.47)($1.17)($1.49)($0.65)($0.47)$0.19

Shares outstanding — basic (M)———7811,0851,2061,3411,3571,3691,418

Shares outstanding — diluted (M)———7811,0851,2061,3411,3571,3691,475

Showing the latest 10 of 12 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.